Gergely, Tamás G.
Drobni, Zsófia D.
Kallikourdis, Marinos
Zhu, Han http://orcid.org/0000-0002-2751-7814
Meijers, Wouter C.
Neilan, Tomas G. http://orcid.org/0000-0003-4356-8176
Rassaf, Tienush
Ferdinandy, Péter
Varga, Zoltán V. http://orcid.org/0000-0002-2758-0784
Article History
Accepted: 12 December 2023
First Online: 26 January 2024
Competing interests
: M.K. is listed as an inventor in a patent on the use of co-stimulation blockade in heart failure. W.C.M. received speaker fees from Daiichi Sankyo and Novartis. T.G.N. has been a consultant for and received fees from Bristol Myers Squibb, CRC Oncology, Genentech, Roche, Roivant, Sanofi and Race Oncology, and has received grant funding from AstraZeneca and Bristol Myers Squibb for work related to immune checkpoint inhibitors. T.R. is a co-founder of Bimyo, a company focusing on the development of cardioprotective peptides; is listed on patents for the use of BNIP3 peptides for the treatment of myocardial infarction; is listed on a patent on the transport and delivery of nitric oxide; and is also listed on a patent of an antihypertensive composition of nitrate or nitrate derivates. P.F. is the founder and CEO of the Pharmahungary Group, a group of research and development companies. All other authors declare no competing interests.